Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$14.19
-2.8%		$10.32
$2.74
▼
$15.02
$4.35B1.326.11 million shs5.64 million shs
Celcuity, Inc. stock logo
CELC
Celcuity
$75.50
-5.1%		$88.00
$44.42
▼
$151.02
$3.69B0.191.07 million shs547,114 shs
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$16.86
-2.4%		$17.12
$12.12
▼
$35.34
$1.03B2.531.09 million shs327,399 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.77
-1.9%		$11.39
$6.28
▼
$13.11
$3.66B-0.17226,467 shs112,021 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-1.55%+18.52%+27.09%+79.90%+190.06%
Celcuity, Inc. stock logo
CELC
Celcuity
+2.77%-0.59%-10.71%-26.34%+60.97%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
+1.95%+4.60%-5.16%+11.20%-29.30%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-3.26%-2.66%-1.08%-7.58%+14.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$14.19
-2.8%		$10.32
$2.74
▼
$15.02
$4.35B1.326.11 million shs5.64 million shs
Celcuity, Inc. stock logo
CELC
Celcuity
$75.50
-5.1%		$88.00
$44.42
▼
$151.02
$3.69B0.191.07 million shs547,114 shs
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$16.86
-2.4%		$17.12
$12.12
▼
$35.34
$1.03B2.531.09 million shs327,399 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.77
-1.9%		$11.39
$6.28
▼
$13.11
$3.66B-0.17226,467 shs112,021 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-1.55%+18.52%+27.09%+79.90%+190.06%
Celcuity, Inc. stock logo
CELC
Celcuity
+2.77%-0.59%-10.71%-26.34%+60.97%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
+1.95%+4.60%-5.16%+11.20%-29.30%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-3.26%-2.66%-1.08%-7.58%+14.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.67
Moderate Buy$13.38-3.32% Downside
Celcuity, Inc. stock logo
CELC
Celcuity
2.83
Moderate Buy$154.25101.47% Upside
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
2.67
Moderate Buy$36.46114.45% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
3.00
Buy$20.5089.92% Upside

Current Analyst Ratings Breakdown

Latest JANX, ABCL, TLX, and CELC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$140.00 ➝ $134.00
9/29/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$17.00
9/25/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
9/24/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$13.00
9/23/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
9/21/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Moderate Buy
9/17/2026
Celcuity, Inc. stock logo
CELC
Celcuity
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$157.00
9/15/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
9/14/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
9/2/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
9/1/2026
Celcuity, Inc. stock logo
CELC
Celcuity
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$75.13M56.46N/AN/A$3.23 per share4.28
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/A$2.17 per shareN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$10M103.95N/AN/A$15.91 per share1.07
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M4.56$0.04 per share268.95$1.23 per share8.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.41M-$0.54N/AN/AN/A-248.83%-17.49%-12.36%11/5/2026 (Estimated)
Celcuity, Inc. stock logo
CELC
Celcuity
-$177.04M-$4.30N/AN/AN/AN/A-350.78%-41.54%11/11/2026 (Estimated)
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$113.62M-$1.64N/AN/AN/AN/A-11.89%-11.13%11/5/2026 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A39.98N/AN/AN/AN/AN/A

Latest JANX, ABCL, TLX, and CELC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Celcuity, Inc. stock logo
CELC
Celcuity
-$1.16-$1.44-$0.28-$1.44$4.42 millionN/A
8/6/2026Q2 2026
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.2513-$0.35-$0.0987-$0.35$19.08 million$10.27 million
8/5/2026Q2 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1640-$0.18-$0.0160-$0.18$7.85 million$4.05 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Celcuity, Inc. stock logo
CELC
Celcuity
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
12.77
12.77
Celcuity, Inc. stock logo
CELC
Celcuity
6.04
8.93
8.93
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
16.35
16.35
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.16
2.01
1.85

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Celcuity, Inc. stock logo
CELC
Celcuity
63.33%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.40%
Celcuity, Inc. stock logo
CELC
Celcuity
13.33%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
7.90%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
562306.61 million219.53 millionOptionable
Celcuity, Inc. stock logo
CELC
Celcuity
15548.93 million42.41 millionOptionable
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
11361.14 million56.31 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,152339.89 millionN/AN/A

Recent News About These Companies

IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®
October 1 at 3:40 AM  |  biospace.comB
IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®
October 1 at 1:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372512/0/en/iba-and-telix-strengthen-ties-through-agreement-to-distribute-artms-s-qis.html
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
September 30 at 10:56 AM  |  zacks.comhttps://www.zacks.com/stock/news/2998180/wall-street-analysts-believe-telix-pharmaceuticals-limited-tlx-could-rally-83-42-here-s-is-how-to-trade?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-2998180
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
September 30 at 7:35 AM  |  manilatimes.netM
Telix Pharmaceuticals wins FDA fast track for BiPASS prostate cancer imaging
September 30 at 7:35 AM  |  msn.comhttps://www.msn.com/en-au/money/general/telix-pharmaceuticals-wins-fda-fast-track-for-bipass-prostate-cancer-imaging/ar-AA2ddYox
Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - Here's Why
September 28 at 2:24 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-sees-strong-trading-volume-heres-why-2026-09-28/
Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Has Average Price Target of $20.50 According to Brokerages
September 28 at 2:46 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056575
Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Now Rated "Buy" by Wall Street Brokerages
September 28 at 2:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-telix-pharmaceuticals-limited-nasdaq-tlx-stock-now-rated-buy-by-wall-street-brokerages-2026-09-28/
Analysts Offer Insights on NA Companies: Ford Motor (F) and Telix Pharmaceuticals Limited Unsponsored ADR (TLX)
September 26, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TLX/pressreleases/4816059/analysts-offer-insights-on-na-companies-ford-motor-f-and-telix-pharmaceuticals-limited-unsponsored-adr-tlx/
Telix Pharmaceuticals (NASDAQ:TLX) Stock Rating Reaffirmed as Buy by HC Wainwright
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-telix-pharmaceuticals-nasdaq-tlx-stock-rating-reaffirmed-as-buy-by-hc-wainwright-2026-09-25/
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Should You Sell?
September 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31048818
Wedbush Reaffirms "Outperform" Rating for Telix Pharmaceuticals (NASDAQ:TLX)
September 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31047032
Telix Pharmaceuticals Issues New Shares Under Employee Stock Plan
September 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-issues-new-shares-under-employee-stock-plan?utm_source=marketbeat.com&utm_medium=referral
Bell Potter Securities upgrades Telix Pharmaceuticals to buy from hold
September 24, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/bell-potter-securities-upgrades-telix-pharmaceuticals-to-buy-from-hold/ar-AA2cUFGc
Telix Pharmaceuticals (ASX:TLX): ITM Deal Shifts Valuation
September 24, 2026  |  kalkinemedia.comK
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up on Analyst Upgrade
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042848
Telix Pharmaceuticals (ASX:TLX) ITM Deal Puts Valuation Back In Focus
September 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/telix-pharmaceuticals-asx-tlx-itm-121359043.html
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's Why
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-shares-gap-down-heres-why-2026-09-23/
Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-telix-pharmaceuticals-nasdaq-tlx-receives-outperform-rating-from-wedbush-2026-09-23/
What could Telix Pharmaceuticals (ASX:TLX) mean for Healthcare Stocks?
September 23, 2026  |  kalkinemedia.comK
Telix Pharmaceuticals (ASX:TLX) Lands $2.35 Billion Deal To Reshape Radiopharmaceutical Reach
September 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/telix-pharmaceuticals-asx-tlx-lands-201701021.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$14.18 -0.41 (-2.78%)
As of 03:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Celcuity stock logo

Celcuity NASDAQ:CELC

$75.50 -4.03 (-5.06%)
As of 03:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$16.86 -0.42 (-2.43%)
As of 03:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$10.77 -0.20 (-1.86%)
As of 03:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas